Gainesville, FLNCT07107334Now EnrollingIRB Ready

Endometrioid Endometrial Adenocarcinoma Clinical Trial in Gainesville, FL

Access cutting-edge endometrioid endometrial adenocarcinoma treatment through this phase 2 clinical trial at a research site in Gainesville. Study-provided care at no cost to qualified participants.

Sponsored by University of Florida

Quick Self-Assessment

See if you qualify for this Gainesville location

Preparing your pre-screening questions…

Expert Care in Gainesville

Access endometrioid endometrial adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related endometrioid endometrial adenocarcinoma treatment provided free

Apply for This Gainesville Location

Check if you qualify for this endometrioid endometrial adenocarcinoma clinical trial in Gainesville, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Gainesville

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Gainesville site if eligible
  4. 4Begin participation

About This Endometrioid Endometrial Adenocarcinoma Study in Gainesville

This study will explore the use of glucagon-like peptide 1 receptor agonist (GLP-1RA) used concurrently with levonorgestrel intrauterine device in patients with poor surgical candidacy for a hysterectomy or patients who are pursuing fertility sparing. GLP-1RA are a class of medications that mimic the natural hormone glucagon-like peptide-1. These medications trigger the pancreas to release insulin which can help lower blood sugar levels and delay gastric emptying. The recent FDA approval of GLP-1RAs has changed the landscape for pharmacotherapy for weight loss. These hormone-based obesity medications are novel and revolutionary in obesity medicine. Liraglutine, semaglutide, and tirzepatide have become exceedingly popular for their effects on weight loss and obesity-related comorbidities. More recently, GLP-1RAs have exhibited risk reduction of various obesity associated cancers, including endometrial cancer but their exact role in prevention and treatment has yet to be measured.

Sponsor: University of Florida

Who Can Participate

Inclusion Criteria

Adults ≥ 18 years old
A pathological diagnosis with in the past 4 months consistent with grade 1 endometrioid endometrial adenocarcinoma or EIN
For subjects with a diagnosis of endometrial intraepithelial neoplasia/grade 1 endometrioid endometrial adenocarcinoma prior to enrollment in the study, and with a diagnosis made outside this institution, the diagnostic material originating from outside the study site will undergo in-house pathology review before enrollment acceptance.
ECOG Performance Status of 0 to 3
For those with endometrial cancer, no extrauterine involvement or myometrial invasion by MRI (preferred) or transvaginal ultrasound
BMI ≥ 30 kg/m2 and one of the following (per medical record or self-report):
Multiple medical co-morbidities (defined as American Society of Anesthesiologists \[ASA\] score ≥ 3) at physician discretion
Fertility desire
Subject has had appropriate age-related breast examinations and imagining prior to study enrollment, as documented in the medical record or via investigator confirmation.
Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.

Exclusion Criteria

Subjects with grade 2 or 3 endometroid or any non-endometrioid histology (i.e., clear cell, carcinoma, serous)
Clinical suspicion of metastatic disease as assessed by the treating physician or confirmed metastatic disease based on imaging
Subjects with abnormal cervical cytology
Subjects who are diagnosed with thyroid cancer, pancreatitis, or multiple endocrine neoplasia syndrome type 2
Subjects who are confirmed to be pregnant or breastfeeding
History of medullary thyroid cancer
Subjects with known current or history of hormonally- sensitive carcinoma (e.g., breast, melanoma)
Subjects actively taking GLP-1RA for more than 14 days at time of consent.
Subjects with levonorgestrel-releasing intrauterine system placed \>45 days prior to study enrollment.
Subjects must not have more than one active malignancy at the time of enrollment (Subjects with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with safety or efficacy assessment of the study \[as determined by the treating physician or approved by the PI\] may be included).
History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician. This includes, but is not limited to, conditions such as New York Heart Association (NYHA) Class IV heart failure.
Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Gainesville?

Yes, this clinical trial (NCT07107334) has an active research site in Gainesville, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Endometrioid Endometrial Adenocarcinoma Treatment Options in Gainesville, FL

If you're searching for endometrioid endometrial adenocarcinoma treatment options in Gainesville, FL, this clinical trial (NCT07107334) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Gainesville research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced endometrioid endometrial adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all endometrioid endometrial adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Gainesville, FL

See all alzheimers disease clinical trials recruiting in Gainesville — not just this study.

Browse Alzheimers Disease Trials in Gainesville →

Browse More Trials by Condition

Alzheimers Disease TrialsEssential Tremor TrialsAtopic Dermatitis TrialsOsteogenesis Imperfecta TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Gainesville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Gainesville, FL